Transaction concentrates Elanco's focus on significant value creation opportunities and accelerates deleveraging progress "Finalizing this transaction marks a significant milestone in concentrating our focus on high-value opportunities in pet health and livestock sustainability while creating balance sheet flexibility. Elanco's positive trajectory, demonstrated by three consecutive quarters of underlying revenue growth, pipeline progress, and our ability to reduce debt, strengthens our value proposition," s ...

Visit: www.hbsslaw.com/investor-fraud/elan Contact the Firm Now: ELAN@hbsslaw.com | 844-916-0895 Elanco Animal Health is facing questions from investors regarding the accuracy of its previous statements concerning the commercial launch timelines for two key products. These products, Zenrelia, a dermatology treatment for pets, and Credelio Quattro, a broad-spectrum parasiticide, were positioned by Elanco as potential "blockbusters." But on June 27, 2024, Elanco significantly revised its launch timelines. The ...

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Ze ...

NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. Why Did Elanco's Stock Drop? With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Ela ...

NEW YORK, July 06, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws. If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated. Why Did Elanco's Stock Drop? Elanco develops products to treat diseases in animals. Two of the most importan ...

文章核心观点 - 公司Elanco Animal Health Incorporated(以下简称Elanco)发布公告,宣布其两款新药物Zenrelia和Credelio Quattro的FDA审批时间表发生变化[1][2] - Zenrelia预计将在2024年第三季度获得FDA批准,商业化推出时间推迟至第四季度[2] - Credelio Quattro预计将在2024年第四季度获得FDA批准,较之前预期的第三季度有所延迟[2] - 该消息公布后,Elanco股价当日下跌11%[3] 公司相关 - Elanco是一家专注于动物健康的公司,主要从事动物药物的研发和销售[1] - 公司正在开发两款新药物Zenrelia和Credelio Quattro,这两款药物的FDA审批时间表发生变化[2] 行业相关 - 动物药物行业受到FDA审批进度的影响较大,审批时间的变化会对公司业绩产生影响[2][3]

Click here to participate in the action. On this news, Elanco's stock price fell $3.69 per share, or 20.53%, to close at $14.28 per share on June 27, 2024. About Bragar Eagel & Squire, P.C.: Contact Information: NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated ("Elanco" or the "Company") (NYSE: ELAN) on behalf of Elanco stockholders. Our investigation conce ...

文章核心观点 - 领先证券法律事务所Bleichmar Fonti & Auld LLP宣布对Elanco Animal Health Incorporated展开调查，因其可能违反联邦证券法，该公司两款重要药物未获FDA六月批准致股价下跌 [5][2][9] 公司情况 - Elanco开发动物疾病治疗产品，其研发管线中两款重要治疗药物Zenrelia和Credelio Quattro正接受FDA审查，前者用于治疗犬类皮炎，后者是广谱口服杀虫剂 [6] 药物审批情况 - 公司曾称FDA有完成审查所需全部数据，所有技术部分包括标签预计在2024年6月底前获批，但6月27日宣布FDA不会在6月批准这两款药物，且Zenrelia会有安全盒装警告 [2] 股价表现 - 受此消息影响，Elanco股价从2024年6月26日的每股17.97美元降至6月27日的每股14.27美元，跌幅超21% [9] 律所调查 - BFA Law正调查Elanco及其部分高管是否就FDA药物批准向投资者作出重大虚假和/或误导性陈述 [9] 投资者权益 - 投资Elanco的投资者可能有法律途径，可向该律所提交信息，代理按风险代理收费，投资者无需承担诉讼费用，律所将寻求法院批准潜在费用和开支 [10]

文章核心观点 - 领先证券法律事务所Bleichmar Fonti & Auld LLP对Elanco Animal Health Incorporated展开调查，因其可能违反联邦证券法，该公司两款重要药物未获FDA六月批准致股价下跌 [1][2][5] 公司情况 - Elanco开发动物疾病治疗产品，两款重要在研药物Zenrelia和Credelio Quattro正接受FDA审查，前者治疗犬类皮炎，后者为广谱口服杀虫剂 [4] 事件情况 - 公司曾称FDA有完成审查所需全部数据，技术部分预计六月底前获批，但6月27日宣布两款药物六月均无法获批，且Zenrelia会有安全盒装警告 [2] - 受此消息影响，公司股价从6月26日的每股17.97美元降至6月27日的每股14.27美元，跌幅超21% [5] - BFA Law调查Elanco及其部分高管是否就FDA药物批准向投资者作出重大虚假或误导性陈述 [5] 投资者建议 - 若投资Elanco，可访问https://www.bfalaw.com/cases - investigations/elanco - animal - health - incorporated获取更多信息，也可提交信息，代理按风险代理收费，投资者无需承担诉讼费用 [3][6] 律所情况 - Bleichmar Fonti & Auld LLP是领先国际律所，代表证券集体诉讼和股东诉讼原告，2023年被ISS SCAS评为前5大原告律所，律师获多项荣誉，近期从特斯拉董事会追回超9亿美元（待法院批准），从梯瓦制药追回4.2亿美元 [7]

文章核心观点 - 股东权利律师事务所Johnson Fistel, LLP调查Elanco Animal Health Incorporated及其高管等是否违反证券法，未及时向投资者披露重大不利信息，并关注投资者损失能否依联邦证券法追回 [1] 调查相关情况 - Johnson Fistel, LLP是全国知名股东权利律师事务所，在加州、纽约、佐治亚州和科罗拉多州设有办公室，代理股东派生诉讼和证券集体诉讼 [4] - 若想加入调查可点击链接，或联系Jim Baker，邮箱jimb@johnsonfistel.com，电话(619) 814 - 4471 [4] 调查聚焦事件 - 2024年6月27日Elanco发布新闻稿更新Zenrelia和Credelio Quattro的FDA预期批准时间，Zenrelia预计2024年第三季度获FDA批准，第四季度商业推出，此前计划第三季度推出；Credelio Quattro预计2024年第四季度获FDA批准，此前预计第三季度获批 [5] 股价影响 - 消息发布后公司股价下跌20%，2024年6月27日收于每股14.28美元 [7]